Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

In contrast to Clovis' share-price collapse, Celgene (CELG) is +8.6% after saying on Friday that...

  • Monday, November 12, 2012, 8:44 AM ET
    In contrast to Clovis' share-price collapse, Celgene (CELG) is +8.6% after saying on Friday that its Abraxane treatment for advanced pancreatic cancer lengthened the survival of patients in a Phase III study. Pancreatic cancer could add up to $1B in sales of Abraxane, which is already approved to treat breast and lung tumors.
Track new comments on this story

This news story has 1 comment:

  •  
    Great news for patients of this terrible disease. There were many anekdotal rumors on cancer web sites on the efficiency of Abraxene in pancreatic cancer. The mechanism involves targeted delivery and thus the compatibility of the drug is much better than of the taxol.
    12 Nov 2012, 08:54 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »